Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial (QUASAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02446795|
Recruitment Status : Unknown
Verified January 2017 by Consorzio Oncotech.
Recruitment status was: Recruiting
First Posted : May 18, 2015
Last Update Posted : January 18, 2017
Clinical Research Technology S.r.l.
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
Publications of Results:
Aparicio LM, Pulido EG, Gallego GA. Sunitinib-induced asthenia: from molecular basis to clinical relief. Cancer Biol Ther. 2011 Nov 1;12(9):765-71. doi: 10.4161/cbt.12.9.18138. Review.
Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011 Apr;59(4):526-40. doi: 10.1016/j.eururo.2011.01.002. Epub 2011 Jan 14. Review.